Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Edwards Lifesciences CorpEW · Entity 3026 | CVP,Strategy/Corp Development | May 27, 2026 | May 27, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Edwards Lifesciences Corp
Report date May 27, 2026 · Filed May 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 98,611 |
Reported balance
After 2026-05-27 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-05-27 · Sale · Disposed 23,145 · Balance 98,611 F1: This transaction was executed in multiple trades at prices ranging from $86.27 to $86.57. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. |
| Common StockSEC Table I · non-derivative | Direct | 22,798.2532 |
Reported balance
Holding disclosure · report date 2026-05-27 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 22,798.2532 |
| Common StockSEC Table I · non-derivative | Indirect401(k) | 30,969.5756 |
Reported balance
Holding disclosure · report date 2026-05-27 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 30,969.5756 |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was executed in multiple trades at prices ranging from $86.27 to $86.57. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 08, 2019 Filed May 8, 2019 22:10 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 300 | $0.00 Strike: $42.73 | $0.00 |
DisclosureSEC source: 0001223203-19-000023 · primary_doc.xml · derivative · entry 6 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 300 shares Expires 2019-05-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2018. Read SEC document |
| May 08, 2019 Filed May 8, 2019 22:10 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 300 | $178.54 | $53,562.00 |
DisclosureSEC source: 0001223203-19-000023 · primary_doc.xml · nonDerivative · entry 2 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,115.3275 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2018. Read SEC document |
| May 08, 2019 Filed May 8, 2019 22:10 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 300 | $42.73 | $12,817.50 |
DisclosureSEC source: 0001223203-19-000023 · primary_doc.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,415.3275 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2018. Read SEC document |
| May 08, 2019 Filed May 10, 2019 23:27 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantPerformance Rights · Derivative | 2,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001223203-19-000037 · primary_doc.xml · derivative · entry 6 BOBO DONALD E JR · CIK 0001196661 · CVP, Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,400 Underlying: Common Stock · 2,400 shares Expires 2026-05-07 F4 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 8, 2019 and scheduled to vest on May 8, 2022. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F4 · shares: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 8, 2019 and scheduled to vest on May 8, 2022. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F4 · derivative.exercise_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 8, 2019 and scheduled to vest on May 8, 2022. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F4 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 8, 2019 and scheduled to vest on May 8, 2022. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F4 · derivative.underlying_shares: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 8, 2019 and scheduled to vest on May 8, 2022. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. Read SEC document |
| May 08, 2019 Filed May 10, 2019 23:27 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantEmployee Stock Option (Right to Acquire) · Derivative | 18,900 | $0.00 Strike: $177.77 | $0.00 |
DisclosureSEC source: 0001223203-19-000037 · primary_doc.xml · derivative · entry 5 BOBO DONALD E JR · CIK 0001196661 · CVP, Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,900 Underlying: Common Stock · 18,900 shares Expires 2026-05-07 F3 · derivative.exercise_date: These options were granted on May 8, 2019 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one month after the grant date in 36 approximately equal annual installments. Read SEC document |
| May 08, 2019 Filed May 10, 2019 23:27 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 1,925 | $0.00 | $0.00 |
DisclosureSEC source: 0001223203-19-000037 · primary_doc.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP, Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,040.3275 F1 · shares: These restricted stock units were granted on May 8, 2019 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become 50% vested three years after the grant date and 50% vested four years after the grant date. Read SEC document |
| April 10, 2019 Filed Apr 10, 2019 22:34 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 300 | $0.00 Strike: $42.73 | $0.00 |
DisclosureSEC source: 0001225208-19-006616 · doc4.xml · derivative · entry 6 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300 Underlying: Common Stock · 300 shares Expires 2019-05-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2018. Read SEC document |
| April 10, 2019 Filed Apr 10, 2019 22:34 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 300 | $189.95 | $56,985.00 |
DisclosureSEC source: 0001225208-19-006616 · doc4.xml · nonDerivative · entry 2 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,115.3275 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2018. Read SEC document |
| April 10, 2019 Filed Apr 10, 2019 22:34 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 300 | $42.73 | $12,817.50 |
DisclosureSEC source: 0001225208-19-006616 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,415.3275 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2018. Read SEC document |
| March 13, 2019 Filed Mar 13, 2019 21:16 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 5,500 | $0.00 Strike: $42.73 | $0.00 |
DisclosureSEC source: 0001225208-19-005217 · doc4.xml · derivative · entry 6 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600 Underlying: Common Stock · 5,500 shares Expires 2019-05-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2018. Read SEC document |
| March 13, 2019 Filed Mar 13, 2019 21:16 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 5,500 | $175.73 | $966,515.00 |
DisclosureSEC source: 0001225208-19-005217 · doc4.xml · nonDerivative · entry 2 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,982.2297 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2018. Read SEC document |
| March 13, 2019 Filed Mar 13, 2019 21:16 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 5,500 | $42.73 | $234,987.50 |
DisclosureSEC source: 0001225208-19-005217 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,482.2297 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2018. Read SEC document |
| February 13, 2019 Filed Feb 13, 2019 22:20 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 5,500 | $0.00 Strike: $42.73 | $0.00 |
DisclosureSEC source: 0001225208-19-002460 · doc4.xml · derivative · entry 6 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,100 Underlying: Common Stock · 5,500 shares Expires 2019-05-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2018. Read SEC document |
| February 13, 2019 Filed Feb 13, 2019 22:20 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 5,500 | $177.75 | $977,625.00 |
DisclosureSEC source: 0001225208-19-002460 · doc4.xml · nonDerivative · entry 2 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,982.2297 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2018. Read SEC document |
| February 13, 2019 Filed Feb 13, 2019 22:20 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 5,500 | $42.73 | $234,987.50 |
DisclosureSEC source: 0001225208-19-002460 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,482.2297 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2018. Read SEC document |
| January 16, 2019 Filed Jan 17, 2019 02:05 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 5,500 | $0.00 Strike: $42.73 | $0.00 |
DisclosureSEC source: 0001225208-19-000913 · doc4.xml · derivative · entry 6 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,600 Underlying: Common Stock · 5,500 shares Expires 2019-05-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2018. Read SEC document |
| January 16, 2019 Filed Jan 17, 2019 02:05 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 5,500 | $162.03 | $891,165.00 |
DisclosureSEC source: 0001225208-19-000913 · doc4.xml · nonDerivative · entry 2 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,982.2297 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2018. Read SEC document |
| January 16, 2019 Filed Jan 17, 2019 02:05 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 5,500 | $42.73 | $234,987.50 |
DisclosureSEC source: 0001225208-19-000913 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,482.2297 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2018. Read SEC document |
| December 12, 2018 Filed Dec 17, 2018 23:20 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 5,500 | $0.00 Strike: $42.73 | $0.00 |
DisclosureSEC source: 0001225208-18-016751 · doc4.xml · derivative · entry 6 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,100 Underlying: Common Stock · 5,500 shares Expires 2019-05-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2018. Read SEC document |
| December 12, 2018 Filed Dec 17, 2018 23:20 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 5,500 | $164.99 | $907,445.00 |
DisclosureSEC source: 0001225208-18-016751 · doc4.xml · nonDerivative · entry 2 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,982.2297 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2018. Read SEC document |
| December 12, 2018 Filed Dec 17, 2018 23:20 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 5,500 | $42.73 | $234,987.50 |
DisclosureSEC source: 0001225208-18-016751 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,482.2297 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2018. F2 · balance_after: Amount reflects (i) approximately 831 shares less which were previously reported as directly held by Insider but are not attributable to Insider and (ii) an additional 176 shares less which were previously reported as directly held by Insider but are held by Insider's son (see footnote (4) below). Read SEC document |
| November 14, 2018 Filed Nov 15, 2018 22:21 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 5,500 | $0.00 Strike: $42.73 | $0.00 |
DisclosureSEC source: 0001225208-18-015562 · doc4.xml · derivative · entry 5 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,600 Underlying: Common Stock · 5,500 shares Expires 2019-05-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2018. Read SEC document |
| November 14, 2018 Filed Nov 15, 2018 22:21 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 5,500 | $149.62 | $822,910.00 |
DisclosureSEC source: 0001225208-18-015562 · doc4.xml · nonDerivative · entry 2 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,989.6269 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2018. Read SEC document |
| November 14, 2018 Filed Nov 15, 2018 22:21 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 5,500 | $42.73 | $234,987.50 |
DisclosureSEC source: 0001225208-18-015562 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,489.6269 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2018. Read SEC document |
| November 06, 2018 Filed Nov 15, 2018 22:21 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GiftCommon Stock | 3,953 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-015562 · doc4.xml · nonDerivative · entry 3 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 46,832 Read SEC document |
| October 10, 2018 Filed Oct 11, 2018 20:24 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 5,500 | $0.00 Strike: $42.73 | $0.00 |
DisclosureSEC source: 0001225208-18-014551 · doc4.xml · derivative · entry 5 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,100 Underlying: Common Stock · 5,500 shares Expires 2019-05-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2018. Read SEC document |
| October 10, 2018 Filed Oct 11, 2018 20:24 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 5,500 | $147.50 | $811,250.00 |
DisclosureSEC source: 0001225208-18-014551 · doc4.xml · nonDerivative · entry 2 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,989.6269 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2018. Read SEC document |
| October 10, 2018 Filed Oct 11, 2018 20:24 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 5,500 | $42.73 | $234,987.50 |
DisclosureSEC source: 0001225208-18-014551 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,489.6269 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2018. Read SEC document |
| September 12, 2018 Filed Sep 14, 2018 20:37 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 5,500 | $0.00 Strike: $42.73 | $0.00 |
DisclosureSEC source: 0001225208-18-013402 · doc4.xml · derivative · entry 5 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,600 Underlying: Common Stock · 5,500 shares Expires 2019-05-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2018. Read SEC document |
| September 12, 2018 Filed Sep 14, 2018 20:37 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 5,500 | $144.16 | $792,880.00 |
DisclosureSEC source: 0001225208-18-013402 · doc4.xml · nonDerivative · entry 2 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,989.6269 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2018. Read SEC document |
| September 12, 2018 Filed Sep 14, 2018 20:37 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 5,500 | $42.73 | $234,987.50 |
DisclosureSEC source: 0001225208-18-013402 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,489.6269 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2018. Read SEC document |
| August 31, 2018 Filed Sep 5, 2018 23:07 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 75 | $144.24 | $10,818.37 |
DisclosureSEC source: 0001225208-18-013192 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,989.6269 Read SEC document |
| August 15, 2018 Filed Aug 17, 2018 20:32 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 5,500 | $0.00 Strike: $42.73 | $0.00 |
DisclosureSEC source: 0001225208-18-012713 · doc4.xml · derivative · entry 5 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,100 Underlying: Common Stock · 5,500 shares Expires 2019-05-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2018. Read SEC document |
| August 15, 2018 Filed Aug 17, 2018 20:32 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 5,500 | $136.73 | $752,015.00 |
DisclosureSEC source: 0001225208-18-012713 · doc4.xml · nonDerivative · entry 2 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,064.6269 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2018. Read SEC document |
| August 15, 2018 Filed Aug 17, 2018 20:32 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 5,500 | $42.73 | $234,987.50 |
DisclosureSEC source: 0001225208-18-012713 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,564.6269 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2018. Read SEC document |
| July 11, 2018 Filed Jul 12, 2018 23:23 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 5,500 | $0.00 Strike: $42.73 | $0.00 |
DisclosureSEC source: 0001225208-18-011637 · doc4.xml · derivative · entry 5 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,600 Underlying: Common Stock · 5,500 shares Expires 2019-05-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2018. Read SEC document |
| July 11, 2018 Filed Jul 12, 2018 23:23 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 5,500 | $145.57 | $800,635.00 |
DisclosureSEC source: 0001225208-18-011637 · doc4.xml · nonDerivative · entry 2 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,064.6269 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2018. Read SEC document |
| July 11, 2018 Filed Jul 12, 2018 23:23 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 5,500 | $42.73 | $234,987.50 |
DisclosureSEC source: 0001225208-18-011637 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,564.6269 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2018. F2 · balance_after: This amount includes quarterly acquisition of shares under the Edwards Lifesciences Corporation Employee Stock Purchase Plan as reflected on the most recent report of the plan administrator Read SEC document |
| June 13, 2018 Filed Jun 15, 2018 20:06 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 5,500 | $0.00 Strike: $42.73 | $0.00 |
DisclosureSEC source: 0001225208-18-010711 · doc4.xml · derivative · entry 5 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,100 Underlying: Common Stock · 5,500 shares Expires 2019-05-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2018. Read SEC document |
| June 13, 2018 Filed Jun 15, 2018 20:06 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 4,000 | $153.22 | $612,861.20 |
DisclosureSEC source: 0001225208-18-010711 · doc4.xml · nonDerivative · entry 3 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 50,785 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2018. Read SEC document |
| June 13, 2018 Filed Jun 15, 2018 20:06 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 5,500 | $150.00 | $825,000.00 |
DisclosureSEC source: 0001225208-18-010711 · doc4.xml · nonDerivative · entry 2 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,012.2823 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2018. Read SEC document |
| June 13, 2018 Filed Jun 15, 2018 20:06 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 5,500 | $42.73 | $234,987.50 |
DisclosureSEC source: 0001225208-18-010711 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,512.2823 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2018. Read SEC document |
| May 23, 2018 Filed May 24, 2018 23:58 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 4,000 | $137.52 | $550,060.80 |
DisclosureSEC source: 0001225208-18-009850 · doc4.xml · nonDerivative · entry 2 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 54,785 F2 · price: This transaction was executed in multiple trades at prices ranging from $137.50 to $137.5450. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 23, 2018 Filed May 24, 2018 23:58 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 6,000 | $137.51 | $825,082.80 |
DisclosureSEC source: 0001225208-18-009850 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,012.2823 F1 · price: This transaction was executed in multiple trades at prices ranging from $137.50 to $137.5850. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 17, 2018 Filed May 22, 2018 00:45 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantPerformance Rights · Derivative | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-009680 · doc4.xml · derivative · entry 5 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Underlying: Common Stock · 3,000 shares Expires 2025-05-16 F4 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 17, 2018 and scheduled to vest on May 17, 2021. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award. F4 · shares: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 17, 2018 and scheduled to vest on May 17, 2021. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award. F4 · derivative.exercise_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 17, 2018 and scheduled to vest on May 17, 2021. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award. F4 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 17, 2018 and scheduled to vest on May 17, 2021. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award. F4 · derivative.underlying_shares: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 17, 2018 and scheduled to vest on May 17, 2021. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award. Read SEC document |
| May 17, 2018 Filed May 22, 2018 00:45 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantEmployee Stock Option (Right to Acquire) · Derivative | 23,500 | $0.00 Strike: $135.83 | $0.00 |
DisclosureSEC source: 0001225208-18-009680 · doc4.xml · derivative · entry 4 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,500 Underlying: Common Stock · 23,500 shares Expires 2025-05-16 F3 · derivative.exercise_date: These options were granted on May 17, 2018 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one month after the grant date in 36 approximately equal annual installments. Read SEC document |
| May 17, 2018 Filed May 22, 2018 00:45 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 2,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-009680 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,012.2823 F1 · shares: These restricted stock units were granted on May 17, 2018 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become 50% vested three years after the grant date and 50% vested four years after the grant date. Read SEC document |
| May 16, 2018 Filed May 19, 2018 00:20 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionPerformance Rights · Derivative | 9,712 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-009579 · doc4.xml · derivative · entry 5 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,712 shares Expires 2018-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On May 14, 2015, the Reporting Person was granted a target number of shares (5,550) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 16, 2018, the Compensation Committee of the Issuer's Board of Directors determined that 175% of the target shares vested as of May 14, 2018, and the actual number of shares vested are reflected on this Form. Such shares became issuable following the May 16, 2018 determination. F1 · shares: On May 14, 2015, the Reporting Person was granted a target number of shares (5,550) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 16, 2018, the Compensation Committee of the Issuer's Board of Directors determined that 175% of the target shares vested as of May 14, 2018, and the actual number of shares vested are reflected on this Form. Such shares became issuable following the May 16, 2018 determination. F1 · price: On May 14, 2015, the Reporting Person was granted a target number of shares (5,550) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 16, 2018, the Compensation Committee of the Issuer's Board of Directors determined that 175% of the target shares vested as of May 14, 2018, and the actual number of shares vested are reflected on this Form. Such shares became issuable following the May 16, 2018 determination. F1 · derivative.exercise_date: On May 14, 2015, the Reporting Person was granted a target number of shares (5,550) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 16, 2018, the Compensation Committee of the Issuer's Board of Directors determined that 175% of the target shares vested as of May 14, 2018, and the actual number of shares vested are reflected on this Form. Such shares became issuable following the May 16, 2018 determination. F1 · derivative.underlying_shares: On May 14, 2015, the Reporting Person was granted a target number of shares (5,550) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 16, 2018, the Compensation Committee of the Issuer's Board of Directors determined that 175% of the target shares vested as of May 14, 2018, and the actual number of shares vested are reflected on this Form. Such shares became issuable following the May 16, 2018 determination. Read SEC document |
| May 16, 2018 Filed May 19, 2018 00:20 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 4,816 | $136.43 | $657,046.88 |
DisclosureSEC source: 0001225208-18-009579 · doc4.xml · nonDerivative · entry 2 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,612.2823 F1 · shares: On May 14, 2015, the Reporting Person was granted a target number of shares (5,550) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 16, 2018, the Compensation Committee of the Issuer's Board of Directors determined that 175% of the target shares vested as of May 14, 2018, and the actual number of shares vested are reflected on this Form. Such shares became issuable following the May 16, 2018 determination. Read SEC document |
| May 16, 2018 Filed May 19, 2018 00:20 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 9,712 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-009579 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,428.2823 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On May 14, 2015, the Reporting Person was granted a target number of shares (5,550) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 16, 2018, the Compensation Committee of the Issuer's Board of Directors determined that 175% of the target shares vested as of May 14, 2018, and the actual number of shares vested are reflected on this Form. Such shares became issuable following the May 16, 2018 determination. F1 · price: On May 14, 2015, the Reporting Person was granted a target number of shares (5,550) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 16, 2018, the Compensation Committee of the Issuer's Board of Directors determined that 175% of the target shares vested as of May 14, 2018, and the actual number of shares vested are reflected on this Form. Such shares became issuable following the May 16, 2018 determination. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.